880 WINTER STREET, WALTHAM, MA
Departure of CFO Jason A. Amello and CMO Chrystal Louis
Retention Program Approved for Key Executives at TScan Therapeutics
Investor Presentation
Termination of Research Collaboration Agreement with Amgen Inc.
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Increases Authorized Shares to 600 Million
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload